EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy of smallpox vaccines against Mpox infections in humans

Melissa M Christodoulidou, Neil A Mabbott iD

Immunotherapy Advances · 01.01.2023 · 3 (1)

DOI: 10.1093/immadv/ltad020 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 07.10.2023. Verfasst von Melissa M Christodoulidou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Edinburgh Medical School, Department of Biomedical Sciences, University of Edinburgh, Edinburgh, UK. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute Strategic Programme, UK Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Mpox virus (MPXV) is endemic in certain countries in Central and West Africa, where several mammalian species, especially rodents, are natural reservoirs. However, the MPXV can infect nonhuman primates and cause zoonotic infections in humans after close contact with an infected animal. Human-to-human transmission of MPXV can also occur through direct close contact with an infected individual or infected materials. In May 2022 an initial cluster of human Mpox cases was identified in the UK, with the first case confirmed in a patient who had recently travelled to Nigeria. The infection subsequently spread via human-to-human transmission within the UK and Mpox cases began to appear in many other countries around the world where the MPXV is not endemic. No specific treatments for MPXV infection in humans are available. However, data from studies undertaken in Zaire in the 1980s revealed that those with a history of smallpox vaccination during the global smallpox eradication campaign also had good cross-protection against MPXV infection. However, the vaccines used during the global eradication campaign are no longer available. During the 2022 global Mpox outbreak over a million doses of the Modified Vaccinia Ankara–Bavarian Nordic (MVA–BN) smallpox vaccine were offered either as pre or postexposure prophylaxis to those at high risk of MPXV infection. Here, we review what has been learned about the efficacy of smallpox vaccines in reducing the incidence of MPXV infections in high-risk close contacts.

Schlagwörter

Stichwörter der Autor:innen

Mpoxefficacyhumansinfectionsvaccines

Autor:innen und Institutionen

  • Edinburgh Medical School, Department of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.
  • The Roslin Institute & Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, Midlothian, UK.

ORCID-Profile: Neil A Mabbott

Förderung

  • Institute Strategic Programme
  • UK Biotechnology and Biological Sciences Research Council

Zitieren

APA

Christodoulidou, M. M., & Mabbott, N. A. (2023). Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy Advances, 3(1). https://doi.org/10.1093/immadv/ltad020

Vancouver

Christodoulidou MM, Mabbott NA. Efficacy of smallpox vaccines against Mpox infections in humans. Immunotherapy Advances. 2023;3(1). doi:10.1093/immadv/ltad020

BibTeX
@article{Christodoulidou2023,
  author = {Christodoulidou, Melissa M and Mabbott, Neil A},
  title = {Efficacy of smallpox vaccines against Mpox infections in humans},
  journal = {Immunotherapy Advances},
  year = {2023},
  volume = {3},
  number = {1},
  doi = {10.1093/immadv/ltad020}
}
Kostenlos starten →